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Background: Paralemmin-1 is a phosphoprotein lipid-anchored to the cytoplasmic face of membranes where it
functions in membrane dynamics, maintenance of cell shape, and process formation. Expression of paralemmin-1
and its major splice variant (Δ exon 8) as well as the extent of posttranslational modifications are tissue- and
development-specific. Paralemmin-1 expression in normal breast and breast cancer tissue has not been described
previously.
Results: Paralemmin-1 mRNA and protein expression was evaluated in ten breast cell lines, 26 primary tumors, and
10 reduction mammoplasty (RM) tissues using real time RT-PCR. Paralemmin-1 splice variants were assessed in
tumor and RM tissues using a series of primers and RT-PCR. Paralemmin-1 protein expression was examined in cell
lines using Western Blots and in 31 ductal carcinomas in situ, 65 infiltrating ductal carcinomas, and 40 RM tissues
using immunohistochemistry. Paralemmin-1 mRNA levels were higher in breast cancers than in RM tissue and
estrogen receptor (ER)-positive tumors had higher transcript levels than ER-negative tumors. The Δ exon 8 splice
variant was detected more frequently in tumor than in RM tissues. Protein expression was consistent with mRNA
results showing higher paralemmin-1 expression in ER-positive tumors.
Conclusions: The differential expression of paralemmin-1 in a subset of breast cancers suggests the existence of
variation in membrane dynamics that may be exploited to improve diagnosis or provide a therapeutic target.
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Paralemmin-1 is a phosphoprotein first identified in
brain tissue and is thought to play a role in controlling
cell shape, plasma membrane dynamics, and cell motil-
ity [1,2]. Paralemmin-1 is lipid-anchored to the cyto-
solic side of the plasma membrane through prenylation
and di-palmitoylation of the COOH terminal cysteine
cluster [2]. Arstikaitis and colleagues [3] identified
paralemmin-1 as a regulator of filopodia induction,
synapse formation, and dendritic spine maturation.
When overexpressed in fibroblasts paralemmin-1 pro-
tein induces cellular expansion and process formation
[2]. Knockdown of paralemmin-1 reduces filopodia and
compromises dendritic spine maturation [3].* Correspondence: karcaro@vasci.umass.edu
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reproduction in any medium, provided the orParalemmin-1 is differentially spliced in a tissue-
specific and developmentally-regulated manner. Alterna-
tive splicing of the eighth exon of paralemmin-1 is the
most common of the splice variants [2] and has been
shown to play a role in the recruitment of AMPA-type
glutamate receptors [3]. The Δ exon 8 splice variant also
has been shown to interact with the third intracellular
loop of the D3 dopamine receptor in the hippocampus
and cerebellum in rat brain as well as in glial and neur-
onal cell cultures [2-4]. These studies suggest that the Δ
exon 8 splice variant may have distinct functions in spe-
cific tissues.
In a global gene expression comparison between two
breast cancer cell lines, paralemmin-1 was over
expressed in the invasive, estrogen-receptor (ER) nega-
tive breast cancer cell line (TMX2-28) as compared to
the non-invasive ER-positive parent cell line (MCF-7)
[5]. Given the function of paralemmin-1 in plasma. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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hypothesized that paralemmin-1 may play a role in the
invasive growth that accompanies metastasis of breast
cancers. Here we examine the mRNA and protein ex-
pression of paralemmin-1 and its splice variants in ER-
positive and ER-negative breast cell lines, primary breast
tumors and tissue from reductive mammoplasty surger-
ies. We found paralemmin-1 to be more frequently
expressed in breast cancers than in reduction mammo-
plasty tissues and more highly expressed in ER-positive
breast cancer as compared to ER-negative cancers.Results
Paralemmin-1 mRNA and protein expression in breast cell
lines
A cDNA microarray comparison between the ER-
positive MCF-7 breast cancer cell line and its tamoxifen-
selected, ER-negative derivative, TMX2-28, had shown
that paralemmin-1 mRNA was more highly expressed (8
times greater) in TMX2-28 cells than in MCF-7 cells [5].
Therefore, to investigate the relationship between
paralemmin-1 expression and ER status, in the present
study we examined the expression of paralemmin-1 in
additional breast cancer and non-tumorigenic breast cell
lines (Table 1). Real time RT-PCR demonstrated that
paralemmin-1 mRNA levels were higher in breast cancer
cell lines than in non-tumorigenic breast cell lines (Fig-
ure 1 top). Three of the six breast cancer lines examined
expressed moderate to high levels of paralemmin-1
mRNA, whereas levels in the three others were low or
undetectable. Of the four non-cancer cell lines, only one
(MCF-10A) had detectable levels of paralemmin-1Table 1 Breast cell lines examined for paralemmin-1
mRNA and protein expression
Cell Line Donor
Age
Pathology ER Paralemmin-1 Expression
RNA Protein (kDa)
MCF-7 69 IDC Pos medium 65, 55
T47D 54 IDC Pos low 65*
ZR-75-1 47 IDC Pos medium 65*, 55
BT-20 74 IDC Neg1 low 65, 55
TMX2-284 69 IDC Neg high 65, 55
MDA-MB-231 51 Adeno Neg low none
MCF-10A 36 NE Neg medium 65
1842 15-66 NE Neg low none
184A13 15-66 NE Neg low none
184AA23 15-66 NE Neg low none
1BT-20 cells express ER mRNA, but do not express ER protein; 2Non-
tumorigenic mammary cell line from Dr. Martha Stamfer’s Laboratory
3Derivative of 184 cells; 4Derivative of MCF-7 cells IDC: Invasive ductal
carcinomas Adeno: Adenocarcinoma; NE: Normal epithelial; Sources: [6-8];
*indicates a faint band.transcript. The higher expression in TMX2-28 as com-
pared to MCF-7 [5] was confirmed. In the whole set of
10 cell lines, however, estrogen receptor status was not a
predictor of paralemmin-1 mRNA levels. Among the six
cancer cell lines examined, paralemmin-1 mRNA levels
were highest in the ER-negative cell line, TMX2-28.
However, the next highest expression levels were in two
ER-positive cell lines, MCF-7 and ZR-75.
Examination of cellular protein by Western Blot ana-
lysis using paralemmin-1 antibody revealed differences
between breast cancer and non-tumorigenic cell lines
(Figure 1 bottom). The protein results were in agree-
ment with the mRNA results: the same cell lines dis-
played high, moderate, or low expression. Both splice
variants of paralemmin-1 (65/55 kDa; +/− exon 8) were
detected in variable proportions in the cancer cell lines.
Only the upper band was present in the non-
tumorigenic MCF-10A cell line. Incubation with the
pre-immune control serum revealed no bands at 55 and
65 kDa (data not shown).
Paralemmin-1 RNA and protein expression in clinical
breast tumors and reduction mammoplasty tissue
Paralemmin-1 mRNA levels were assessed in frozen
breast cancer tumor tissue from 26 cases and in 10 re-
duction mammoplasty specimens. Using real time RT-
PCR, relative paralemmin-1 values were found to range
over 270 fold; from a low of 0.03 to a high of 8.23 rela-
tive units (Figure 2). In contrast to the cell line data,
paralemmin-1 expression correlated with ER status in
tumors. Benign breast epithelial cells constitutively ex-
press focal low levels of hormone receptors.
Paralemmin-1 was significantly higher in ER-positive as
compared to ER-negative tumors (p < 0.001) and in ER-
positive tumors as compared to reduction mammoplasty
tissue (p < 0.01). There was no significant difference in
paralemmin-1 levels between ER-negative tumors and
reduction mammoplasty tissue (p > 0.05).
Paralemmin-1 protein expression was examined
immunohistochemically using tissue microarrays
(TMA) constructed from formalin-fixed and paraffin
embedded (FFPE) tissue of 40 RM, 31 ductal carcin-
oma in situ (DCIS) and 65 invasive ductal carcinoma
(IDC) cases. In benign reduction mammoplasty breast
tissue paralemmin-1 immunostaining was focally
present in glandular epithelial and myoepithelial cells,
with variability in intensity (weak to strong) and in
percentage of cells staining within each case and be-
tween cases. Paralemmin-1 was constitutively expressed
in vascular endothelial cells and variably expressed in
stromal cells. In this study we focused on evaluating
paralemmin-1 staining characteristics of benign epithe-
lial cells in RM and tumor epithelial cells. Figure 3



















































Figure 1 Paralemmin-1 is differentially expressed in breast epithelial cell lines. RNA and protein lysates were isolated from tumorigenic and
non-tumorigenic breast cell lines. Top: Real time qRT-PCR shows mRNA expression of paralemmin-1; means and S.E. from three separate cell
cultures are presented; ER-positive cell lines, (hatched bars), ER-negative cell lines (solid bars). Bottom: Protein lysates (15 μg) were probed for
paralemmin-1 expression by Western immunoblotting. Image is a representative of at least three separate experiments with different biological
samples.
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the stain, and shows paralemmin-1 staining in epithe-
lial tumor cells to be primarily localized to the cell
membrane (inserts) (see Methods for details of scoring
and analysis). Figure 4 shows paralemmin-1 expression
in representative RM (A and B) and IDC (C and D)
cases. Roughly 70% of both the DCIS and IDC cases
showed strong reactivity to the paralemmin-1 antibody
(Table 2). In contrast, only 27% of RM cases were
scored as strong, the remainder showed little to no































































































Figure 2 Paralemmin-1 mRNA is highly expressed in ER-positive hum
in 26 frozen breast carcinoma tissue (T) and 10 reduction mammoplasty (R
were assigned the numbers 1–18 (red hatched bars) while ER-negative tum
1 expression.Examination of the relationship between paralemmin-1
staining and hormone receptor status revealed a trend
for higher paralemmin-1 expression in tumors that were
positive for ER and/or progesterone receptor (PR).
Greater than 70% of ER and/or PR-positive tumors
were scored as having high levels of paralemmin-1. In
contrast, in tumors lacking ER and/or PR, paralemmin-1
levels were equally divided between weak and strong. No
relationship between human epidermal growth factor re-
ceptor (HER2) status and paralemmin-1 levels was
























































an tumor samples. Gene expression of paralemmin-1 was determined
M) samples (open bars) using real time RT-PCR. ER-positive tumors
ors were assigned 19–30 (solid bars) and then sorted by paralemmin-
0 1 2 3
Figure 3 Scoring system used to evaluate paralemmin-1 expression in TMA from breast tumors and reduction mammoplasty
specimens. Intensity of immunoreactivity of epithelial cells was used to assign scores of 0, 1, 2, and 3. A 0 was little to no staining, a 1 was
considered to be “light” intensity of staining; a 2 was considered to be “moderate” intensity of staining, a 3 was considered to be “strong”
intensity of staining. Images are from a DCIS TMA with inset in score 1, 2 and 3 images showing increasing intensity of paralemmin-1 plasma
membrane staining in tumor cells. Image for score 0 shows negative paralemmin-1 staining in tumor cells and small peritumoral lymphocytes
(left). Intratumoral and peritumoral vascular endothelial cells (*) and elongated stromal cells are positive for paralemmin-1. Scale bars 50 micron.
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tumors and reduction mammoplasty tissues
RNA from nine cell lines, and from 24 of the 26 tumor
samples and all ten of the RM samples shown in Figure 2A
C
Figure 4 Paralemmin-1 expression in breast epithelial cells is primaril
tumor tissue than reduction mammoplasty. Breast tumor TMAs and red
described in the Methods. Representative images of paralemmin-1 immuno
magnification) show partial staining in terminal duct and acinar ductal epit
cells (image B *). In contrast, in tumor tissues (C and D, high magnification
cells where the staining is localized to the cell membrane. Scale bar imagewas examined for the presence of paralemmin-1 splice
variants; five primer sets designed to detect mRNA miss-
ing exons 4, 5, 6, 7, or 8 (Table 3) were used in RT-PCR
to determine the number and size of products. PrimersB
D
y localized to the cell membrane and is more highly expressed in
uction mammoplasty tissues were prepared, stained, and scored as
reactivity in reduction mammoplasty tissues (A and B, low and high
helial cells. Paralemmin-1 is present in stromal cells and endothelial
) significant immunoreactivity is present in the malignant epithelial
A 100 micron. Scale bars image B, C, D 50 micron.
Table 2 Paralemmin-1 protein expression in reduction mammoplasty and breast cancer cases
RM DCIS IDC DCIS & IDC
ER PR HER2
Pos Neg Pos Neg Pos Neg
Weak 29 (73) 7 (23) 20 (31) 21 (26) 8 (57) 16 (23) 12 (48) 7 (29) 20 (30)
Strong 11 (27) 24 (77) 45 (65) 60 (74) 6 (43) 54 (77) 13 (52) 17 (71) 47 (70)
Number and (percent) of cases in each category that were scored either weak or strong for paralemmin-1 protein expression. RM: reduction mammoplasty; DCIS:
ductal carcinoma in situ; IDC: invasive ductal carcinoma; ER: estrogen receptor; PR: progesterone receptor; HER2: human epidermal growth factor receptor 2.
Turk et al. Cancer Cell International 2012, 12:17 Page 5 of 9
http://www.cancerci.com/content/12/1/17for detecting variants missing exons 4, 5, or 7 yielded
only full length products in all cell lines, tumor and RM
samples examined (data not shown). Primer set 6 yielded
full length products in all cell lines, tumor and RM tis-
sues and also resulted in a second smaller product in
one tumor, indicating that a single tumor expressed the
exon 6-deleted splice variant (data not shown). In con-
trast, primer set 8 revealed the presence of the exon 8
splice variant. Of the nine cell lines examined, all
expressed the full length product and 7 had a robust sig-
nal for the splice variant. Similarly, all 24 of the tumor
samples expressed both the full length and Δ exon 8
splice variant, whereas in 9 out of 10 RM samples the
splice variant was clearly less abundant or undetectable
(Figure 5). Note that the cDNA visualized in the gel are
the products of 45 PCR cycles. Therefore, while several
cell lines and all the RM samples had low levels of
paralemmin-1 mRNA as evaluated by real time RT-PCR
(shown in Figure 1 top and Figure 2) all of these samples
yielded paralemmin-1 PCR products after 45 cycles.
Discussion
Paralemmin-1 is expressed in numerous tissues but is
most highly expressed in the brain, where it is thought
to affect plasma membrane dynamics, cell shape [2], and
ultimately the development and plasticity of the nervous
system. It may do so by serving as an adaptor protein
that connects membrane proteins with each other, with











antisense CCGCTTTGTGGATGAGTTCproperties of paralemmin-1 might implicate this protein
not only in normal morphogenesis but also abnormal
development and cancer. Here we show for the first time
that paralemmin-1 is expressed in breast cancer cell
lines and human breast cancers.
Our discovery of paralemmin-1 overexpression in
breast cancer cell lines came from a cDNA array com-
parison between the ER-positive breast cancer cell line,
MCF-7, and its tamoxifen-selected, ER-negative deriva-
tive, TMX2-28. [5]. We proposed that the overexpres-
sion of paralemmin-1 may contribute to the invasive
nature of the TMX2-28 cells, and possibly to the greater
metastatic potential of ER-negative breast cancers.
Therefore, we examined paralemmin-1 RNA and protein
expression in a larger sample of 10 breast cell lines.
Contrary to our expectation, paralemmin-1 expression
was not inversely correlated with ER status among the
tumorigenic and non-tumorigenic cell lines we exam-
ined. Furthermore, when we examined RNA levels in 26
primary breast tumors we found paralemmin-1 expres-
sion to be significantly higher in ER-positive as com-
pared to ER-negative tumors. This finding was
confirmed when we examined tissue samples by immu-
nohistochemistry; a greater percentage of ER-positive
tumors were scored as having ‘high’ levels of
paralemmin-1 protein, suggesting that paralemmin-1 ex-
pression may still play a role in the differences observed
between ER-positive and ER-negative breast tumors. Al-
though it is conceivable that hormonal status mayparalemmin-1












T-18   T-20    T-21    T-22    T-23    T-24    T-25 T-27 T-28 T-29 T-35 T-36 Water
275bp-
143bp-
RM-1   RM-4    RM-5 RM-6   RM-7  RM-8   RM-10  RM-17 RM-18  RM-21 Water
275bp-
143bp-
T-3      T-4       T-5       T-7      T-8       T-9      T-10     T-11     T-12     T-13    T-14    T-17
275bp-
143bp-
TMX  MCF7   231     10A    184    184A1  AA2   Water     T47D ZR751
275bp-
143bp-
Figure 5 Tumor tissues and breast cell lines express a higher proportion of the Δ exon 8 splice variant of paralemmin-1 than do
reduction mammoplasty tissues. RNA was isolated and amplified with RT-PCR analysis using a primer set to detect Δ exon 8 splice variant. RT-
PCR products were separated on a 2% low melting agarose gel and visualized by ethidium bromide. The full abbreviations of the cell lines are in
Table 1. Tumor tissue samples are represented by the prefix T and reduction mammoplasty tissue samples are represented by the prefix R.
Numbers on the left of the figures represent the full length product (275 bp) and the Δ exon 8 splice variant (143 bp).
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benign breast epithelium, we did not evaluate this pos-
sible association which is beyond the scope of this study.
Kutzleb and colleagues [1] investigated the cellular
and subcellular localization of paralemmin-1 in rat brain
and kidneys. Their study revealed that paralemmin-1 in
the brain was widely distributed in most neuron cell
bodies, axons, dendrites and glial processes, while in the
kidney paralemmin-1 showed differential expression
based on the cell type with a mosaic of paralemmin-1-
positive and -negative cells in the proximal and distal
tubules, parietal epithelium of Bowman’s capsule and the
endothelium of many blood vessels. At a subcellular
level paralemmin-1 has been shown to concentrate at
the apical membranes of adrenal chromaffin cells, but at
the basolateral membranes of proximal and distal tubule
cells in the kidney. Paralemmin-1 detected in the cyto-
plasm was usually associated with endomembranes.
The present study provides the first histological
characterization of paralemmin-1 immunolocalization in
normal and cancerous mammary tissue. In the breast
paralemmin-1 is constitutively expressed in vascular
endothelial cells (lymphatic and small blood vessel), and
variably expressed in stromal cells (not further defined).
Paralemmin-1 is focally expressed in breast ducts and
lobules, showing variable expression in epithelial cells
within each case and between cases, from no staining tostrong focal staining. The subcellular localization of
paralemmin-1 in breast epithelium is consistent with
other tissue types: paralemmin-1 was primarily detected
at the cell membrane and to a much lesser extent in the
cytoplasm. The major difference between paralemmin-1
staining in normal breast tissue (RM) and breast cancer
(DCIS and IDC) was the greater frequency of strong
staining in cancer tissue.
There have been only a few reports of paralemmin-1
expression in cancer tissue. In two reports paralemmin-
1 was identified through mRNA microarray analyses as
being upregulated in cancer cells. Paralemmin-1 was
upregulated in androgen-independent relative to both
androgen-dependent tumors and to normal controls in a
mouse prostate model [9], and high levels of
paralemmin-1 and paralemmin-2-AKAP2 expression
were correlated with an invasive morphological pheno-
type of breast cancer cell lines [10].
Duncavage and colleagues [11] investigated the expres-
sion of paralemmin-2 in non-small cell lung carcinomas
because it is a potential target of the microRNA-221,
which they showed to be down regulated in nonrecur-
rent tumors. However, paralemmin-2 was equally
expressed in both recurrent and nonrecurrent non-small
cell lung carcinomas and it was not determined whether
paralemmin-2 levels were higher in tumors than in nor-
mal tissue. In the present report we not only found that
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breast tumors, but also that paralemmin-1 expression
was greater in tumor tissues than in RM tissues. We
have not examined the expression of benign epithelium
adjacent to tumor, however our observations in RM tis-
sue suggest that this protein is expressed at low levels in
normal breast tissue.
Phosphorylation and mRNA splicing of paralemmin-1
is tissue-specific, developmentally regulated and contri-
butes to the electrophoretic heterogeneity frequently
seen on Western Blots. Amino acids 154–230 of para-
lemmin-1, which correspond to exon 8 of the mRNA se-
quence, have been shown to interact with the third
intracellular loop of the D3 dopamine receptor in the
hippocampus and cerebellum in rat brain, and in glial
and neuronal cell cultures [4]. Thus variants in which
exon 8 is spliced out of the RNA likely result in specific
changes in paralemmin-1 function in different tissue
types. In the present study we detected significant ex-
pression of paralemmin-1 RNA missing exon 8 in both
ER-positive and ER-negative breast cancers. In contrast,
there was very little expression of the Δ exon 8 splice
variant in the RM tissue. At present we do not know
whether normal tissue adjacent to the cancer expresses
paralemmin-1 or the Δ exon 8 splice variant. Use of
laser-capture microdissection to isolate RNA from
tumor and adjacent benign tissue may be valuable in de-
fining the expression and role of paralemmin-1 in breast
carcinogenesis.
Methods
Cell culture and RNA purification
TMX2-28 cells were kindly provided by Dr. John Gierthy
(Wadsworth Center, Albany, NY). MCF-7 and BT-20
cells were purchased from the American Type Culture
Collection (Manassas, VA). The cell lines 184, 184A1,
and 184AA2 were generous gifts from Dr. Martha
Stampfer (Ernest Orlando Lawrence Berkeley National
Laboratory, Berkeley, CA). MDA-MB-231, T47D, ZR75,
and MCF-10A cells were obtained from the Wadsworth
Center (Albany, NY). TMX2-28 and MCF-7 cells were
grown in Dulbecco’s modified eagle medium (DMEM;
without phenol red) supplemented with 5% calf serum
(Hyclone, Logan, UT), 2.0 mmol/L of L-glutamine,
0.1 mmol/L of nonessential amino acids, 10 ng/mL of
insulin, 100 units/mL of penicillin, and 100 μg/mL of
streptomycin. T47-D, ZR-75, BT-20 and MDA-MB-231
cells were maintained in complete growth medium,
which included 10% FBS according to the American
Type Culture Collection protocol. MCF-10A were grown
in mammary epithelial growth medium (Clonetics,
Walkersville, MD) which contains growth factors but no
serum, whereas 184, 184A1, and 184AA2 were cultured
in mammary epithelial growth medium according toDr. M. Stampfer’s protocol as posted on her website [12].
Cells were maintained in a humidified incubator at 37°C
with 5% CO2. RNA was isolated from cell cultures with
TRI Reagent (Molecular Research, Cincinnati, OH)
according to the manufacturer’s protocol. Isolated RNA
was further purified using the Qiagen RNeasy kit with
on-column DNase digestion (Qiagen, Valencia, CA).
Protein isolation and western immunoblotting
Cell cultures were lysed with pre-chilled SDS buffer (1%
SDS and .60 mM Tris–HCl, pH 5) and extracts were
used for Western immunoblotting. Protein lysates
(15 μg) were mixed with NuPage sample buffer and re-
ducing agent (Invitrogen, Carlsbad, CA), heated at 70°C
for 10 min and then separated on a 10% Tris–HCl poly-
acrylamide gel using the Mini-PROTEAN 3 cell (Bio-
Rad, Hercules, CA) according to the manufacturer’s
protocol. Separated proteins were transferred to an
Immun-Blot PVDF membrane using the Mini Trans-
Blot electrophoretic transfer cell and protocol (Bio-Rad,
Hercules, CA). Membranes were incubated in blocking
buffer (5% nonfat dry milk/TBS and 0.1% Tween 20) for
30 min at room temperature with gentle shaking, and
then incubated with anti-paralemmin-1 rabbit polyclonal
antibody diluted 1:100,000 overnight at 4°C, followed by
incubation with the secondary antibody (anti-rabbit IgG
linked to horseradish peroxidase; diluted 1:2,000; Cell
Signaling Technology, Beverly, MA) for 1 h at room
temperature. Chemiluminescent signals were detected
with the SuperSignal West Pico kit and protocol (Pierce,
Rockford, IL). Membranes were stripped according to
manufacturer’s protocol using Restore stripping buffer
(Thermo Scientific, Rockford, IL) and reprobed for gly-
ceraldehyde 3-phosphate dehydrogenase (GAPDH ; Cell
Signaling Technology; diluted 1:10,000) overnight at 4°C,
followed by incubation with the secondary antibody
(anti-rabbit IgG linked to horseradish peroxidase; diluted
1:2,000; Santa Cruz Biotechnology, Santa Cruz, CA) for
1 h at room temperature.
Real-Time RT-PCR
Real-time RT-PCR was performed as previously
described [5]. RNA samples were reverse transcribed
and amplified using the One-Step RT-PCR kit (Qiagen,
Valencia, CA) in the Roche Light Cycler (Roche, Indian-
apolis, IN). Total RNA (75 ng) was incubated with Qia-
gen RT-PCR master mix including primers (25 μmol/L
each) and SYBR Green I nucleic acid stain (diluted
1:5000; Molecular Probes, Eugene, OR) in pre-cooled ca-
pillaries (Roche, Indianapolis, IN) and was reverse tran-
scribed. Following reverse transcription, samples were
heated, to activate the HotStar Taq DNA polymerase
and to simultaneously inactivate the reverse trans-
criptase. The generation of amplified products was
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calating SYBR Green. Relative mRNA levels were nor-
malized to hypoxanthine ribosyltransferase (HPRT)
levels to control for RNA quality and concentration.
Gene-specific primers were designed using Primer3 [13]:
HPRT NM_000194: ACCCCACGAAGTGTTGGATA (nu-
cleotide 587, sense), AAGCAGATGGCCACAGAACT
(nucleotide 834, antisense); Paralemmin-1 NM_002579:




Institutional Review Board approval was obtained from
Baystate Medical Center, Springfield, MA, and all sam-
ples, both frozen and fixed were identified numerically
to maintain patient anonymity. For tumor tissues, grade,
ER, PR, and HER2 status were recorded at the time the
sample was collected.
RNA analysis: Twenty-six frozen breast tumor samples
were retrieved from Baystate Medical Center, Depart-
ment of Surgical Pathology, sectioned to ≤0.5 cm in
thickness and immediately placed in pre-chilled RNA
Later-Ice (Ambion, Austin, TX) for 24 hours, at which
time tumor samples (20–30 mg) were homogenized and
RNA isolated using the Qiagen RNeasy Fibrous Tissue
kit. Ten fresh RM samples were collected at surgery
(Baystate Medical Center) and snap frozen. RNA was
isolated from RM using RNeasy mini columns (Qiagen,
Valencia, CA) followed by a cleanup with Turbo DNA-
free (Ambion, Austin TX).
Tissue microarrays: Ninety-one FFPE primary breast
carcinomas (31 DCIS and 65 IDC) and 40 FFPE RM tis-
sue samples were retrieved from Baystate Medical Cen-
ter, Department of Pathology.
Tissue microarrays immunohistochemistry
Tissue microarrays (TMAs) were constructed by extract-
ing three 1.0-mm diameter cores from each FFPE tissue
block and re-embedding them into a recipient paraffin
block containing holes spaced 2.0 mm apart. A total of
five TMAs were prepared containing tissue from 40 RM
cases (two TMAs), 31 DCIS cases (one TMA), and 65
IDC cases (two TMAs). Four-micron tissue sections
were placed on charged slides, deparaffinized in xylene,
and rehydrated in graded ethanol solutions. Slides were
rinsed in water and incubated in Citra Plus Buffer (Bio-
Genex, San Ramon, CA) under the following conditions
for antigen retrieval: microwave for 3 min, cool for
1 min, heat at 98°C for 10 min, and cool for 20 min.
Staining was performed on a Dako Autostainer using
anti-paralemmin-1 rabbit antibody diluted 1:5000 [1]and Dako Envision Plus labeled polymer horseradish
peroxidase reagents. Two anatomic pathologists inde-
pendently and blindly scored a slide from each TMA for
paralemmin-1 immunoreactivity, assigning values of 0
through 3 for the intensity of staining and descriptors of
focal (low) or diffuse (high) or variable for the percent-
age of tumor cells stained. After at least three days
elapsed, each pathologist, without access to their previ-
ous scores, examined and scored a second slide from
each of the five TMAs. For each case, the highest score
given to any of the three punches was used for analysis.
The intensity scores of 0 and 1 were classified as ‘weak
staining’ and scores of 2 and 3 were classified as ‘strong
staining’.
RT-PCR and analysis of exon splice variants
RNA samples from breast cell lines, frozen breast
tumors and RM tissue were amplified as described above
except the SYBR Green was substituted with RNase-
free water. The PCR products were separated by elec-
trophoresis on a 2.0% low melting point agarose gel
and visualized with ethidium bromide. Exon-specific pri-
mers for paralemmin-1 (Table 3) were designed using
Primer3, and checked for extendible primer dimers using
PerlPrimer [14]. Each set was expected to yield either
one or two bands. Two bands indicate the expression of
both the full length and exon deleted products; one band
indicates expression of only the full length (larger) or
exon-deleted (smaller) product.
Statistical analyses
Data in Figures 1 and 2 were analyzed and graphed with
GraphPad Prism version 3.02 (GraphPad Software, Inc.,
San Diego, CA). Mann–Whitney U tests (significance set
at P < 0.05) were used to compare ER status and
paralemmin-1 expression in breast tumors, and to com-
pare paralemmin-1 levels between RM and tumors.
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